Skip to content

Study · Non-randomized trial · 1978

4 results

Intramuscular or intravenous glucagon for sulphonylurea hypoglycaemia?

Taylor JR, Sherratt HS, Davies DM

European journal of clinical pharmacology1 Nov 1978Cited by 3 (Europe PMC)

PMID363433 (opens in a new tab)DOI10.1007/bf00607443 (opens in a new tab)PepBankPUB-00363433
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In normal subjects and diabetic patients studied before and during chlorpropamide treatment, glucagon raised blood glucose in all subjects.

    In plain wordsIn normal subjects and diabetic patients, glucagon raised blood glucose.

    Peptide
    Glucagon
    Outcome
    IncreaseBlood glucose rise
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In all subjects glucagon raised blood sugar concentrations,
    1 context sentence
    Summary · context
    Because of the differing opinions on the value of glucagon and the best way of administering it in severe hypoglycaemia induced by sulphonylurea drugs, experiments were conducted on normal subjects, and in diabetic patients before and during treatment with chlorpropamide.
  2. 02HumanNon-randomized trialEfficacy outcome

    In the studied subjects, intramuscular glucagon produced a greater blood glucose increase than intravenous glucagon.

    In plain wordsIn the studied subjects, intramuscular glucagon raised blood glucose more than intravenous glucagon.

    Peptide
    Glucagon
    Outcome
    IncreaseMagnitude of blood glucose rise by route
    Study

    n: not reported in source

    Comparator
    Intravenous glucagon
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intramuscularAs given in this study (human).

    Source sentences

    Summary
    In all subjects glucagon raised blood sugar concentrations, and produced a greater and more prolonged increase in blood glucose concentrations when given intramuscularly than when given intravenously.
    1 context sentence
    Summary · context
    Because of the differing opinions on the value of glucagon and the best way of administering it in severe hypoglycaemia induced by sulphonylurea drugs, experiments were conducted on normal subjects, and in diabetic patients before and during treatment with chlorpropamide.
  3. 03HumanNon-randomized trialEfficacy outcome

    In the studied subjects, intramuscular glucagon produced a more prolonged blood glucose increase than intravenous glucagon.

    In plain wordsIn the studied subjects, the glucose rise lasted longer with intramuscular glucagon than with intravenous glucagon.

    Peptide
    Glucagon
    Outcome
    IncreaseDuration of blood glucose rise by route
    Study

    n: not reported in source

    Comparator
    Intravenous glucagon
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intramuscularAs given in this study (human).

    Source sentences

    Summary
    In all subjects glucagon raised blood sugar concentrations, and produced a greater and more prolonged increase in blood glucose concentrations when given intramuscularly than when given intravenously.
    1 context sentence
    Summary · context
    Because of the differing opinions on the value of glucagon and the best way of administering it in severe hypoglycaemia induced by sulphonylurea drugs, experiments were conducted on normal subjects, and in diabetic patients before and during treatment with chlorpropamide.
  4. 04HumanNon-randomized trialSafety outcome

    In the subjects studied with glucagon, hypoglycaemia did not occur in any subject.

    In plain wordsNo studied subject developed low blood glucose with glucagon.

    Peptide
    Glucagon
    Outcome
    No significant changeHypoglycaemia
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Hypoglycaemia did not occur in any subject.
    1 context sentence
    Summary · context
    Because of the differing opinions on the value of glucagon and the best way of administering it in severe hypoglycaemia induced by sulphonylurea drugs, experiments were conducted on normal subjects, and in diabetic patients before and during treatment with chlorpropamide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.